InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Fenton Mary Kay, Chief Financial Officer. Director active across 2 companies, notably Talaris Therapeutics, Inc.. In total, 7 disclosures have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €51k. Activity tracked since 31 December 2021. The latest transaction was filed on 20 February 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Fenton Mary Kay
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
4,398 shares@ US$13.6299.7% of flowCommon StockSEC:0001193125-26-064261:0
68,750 shares0Common StockSEC:0001193125-26-059637:0
27 shares@ US$6.490.3% of flowCommon StockSEC:0001193125-26-002687:0
60,000 shares0Common StockSEC:0000950170-25-025027:0
12,946 shares@ US$3.0861.4% of flowCommon StockSEC:0001209191-23-041617:0
80,000 shares0Common StockSEC:0000899243-22-030928:0
1,000 shares@ US$13.0050.0% of flowCommon StockSEC:0000899243-22-004201:0
7 of 7 declarations
About Fenton Mary Kay
Mary Kay Fenton is the Chief Financial Officer at Talaris Therapeutics, Inc. She oversees the company's financial operations, ensuring compliance and risk management. Her expertise is essential for navigating the financial challenges the company faces.
